Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Naoshi Kunimura
Institution:
Fujimoto Pharmaceutical Corporation (Japan)
Observed institution:
Fujimoto Pharmaceutical Corporation (Japan)
ORCID:
0009-0007-8572-1729
Observed ORCID:
0009-0007-8572-1729
OpenAlex ID:
A5069334608
FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
·
Cancer Research Communications
·
8
PDF
Design, synthesis, and evaluation of a novel protein degrader FPFT-2216
2025
·
Yasuyuki Ueda
, Takashi Ando
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
6
TABLE 1 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
FIGURE 1 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
TABLE 2 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
FIGURE 4 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
Figure S4 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
Figure S1 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
FIGURE 2 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
FIGURE 3 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
Figure S2 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
Data from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
Table S3 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
PDF
Table S1 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
PDF
Table S2 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
PDF
Figure S3 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
Table S5 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
PDF
FIGURE 5 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
Table S4 from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
PDF
Data from FPFT-2216, a Novel Anti-lymphoma Compound, Induces Simultaneous Degradation of IKZF1/3 and CK1α to Activate p53 and Inhibit NFκB Signaling
2024
·
Daiki Kanaoka
, Mitsuo Yamada
, et al.
Show more works
View as search
Works count:
20
Citation count:
14
H-index:
2
I10-index:
Year
Topic
Type
